Literature DB >> 28541437

Hyperferritinemia and inflammation.

Kate F Kernan1, Joseph A Carcillo1.   

Abstract

Understanding of ferritin biology has traditionally centered on its role in iron storage and homeostasis, with low ferritin levels indicative of deficiency and high levels indicative of primary or secondary hemochromatosis. However, further work has shown that iron, redox biology and inflammation are inexorably linked. During infection, increased ferritin levels represent an important host defense mechanism that deprives bacterial growth of iron and protects immune cell function. It may also be protective, limiting the production of free radicals and mediating immunomodulation. Additionally, hyperferritinemia is a key acute-phase reactants, used by clinicians as an indication for therapeutic intervention, aimed at controlling inflammation in high-risk patients. One school of thought maintains that hyperferritinemia is an 'innocent bystander' biomarker of uncontrolled inflammation that can be used to gauge effectiveness of intervention. Other schools of thought maintain that ferritin induction could be a protective negative regulatory loop. Others maintain that ferritin is a key mediator of immune dysregulation, especially in extreme hyperferritinemia, via direct immune-suppressive and pro-inflammatory effects. There is a clear need for further investigation of the role of ferritin in uncontrolled inflammatory conditions both as a biomarker and mediator of disease because its occurrence identifies patients with high mortality risk and its resolution predicts their improved survival. © The Japanese Society for Immunology. 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ferritin; hemophagocytic lymphohistiocytosis; hemophagocytosis; iron; macrophage activation

Mesh:

Substances:

Year:  2017        PMID: 28541437      PMCID: PMC5890889          DOI: 10.1093/intimm/dxx031

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  104 in total

1.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

2.  Ferritin levels in children with severe sepsis and septic shock.

Authors:  Pedro Celiny Ramos Garcia; Fernanda Longhi; Ricardo Garcia Branco; Jefferson Pedro Piva; Dani Lacks; Robert Charles Tasker
Journal:  Acta Paediatr       Date:  2007-12       Impact factor: 2.299

3.  Suppressive effects in vivo of purified recombinant human H-subunit (acidic) ferritin on murine myelopoiesis.

Authors:  H E Broxmeyer; D E Williams; K Geissler; G Hangoc; S Cooper; D C Bicknell; S Levi; P Arosio
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

4.  Increased release of ferritin and iron by iron-loaded alveolar macrophages in cigarette smokers.

Authors:  L J Wesselius; M E Nelson; B S Skikne
Journal:  Am J Respir Crit Care Med       Date:  1994-09       Impact factor: 21.405

5.  Ferritin synthesis in inflammation. II. Mechanism of increased ferritin synthesis.

Authors:  A M Konijn; N Carmel; R Levy; C Hershko
Journal:  Br J Haematol       Date:  1981-11       Impact factor: 6.998

6.  The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis.

Authors:  Adriana Donovan; Christine A Lima; Jack L Pinkus; Geraldine S Pinkus; Leonard I Zon; Sylvie Robine; Nancy C Andrews
Journal:  Cell Metab       Date:  2005-03       Impact factor: 27.287

7.  Interleukin 1 induces ferritin heavy chain in human muscle cells.

Authors:  Y Wei; S C Miller; Y Tsuji; S V Torti; F M Torti
Journal:  Biochem Biophys Res Commun       Date:  1990-05-31       Impact factor: 3.575

8.  Etiology of hypoferremia in a recently sedentary Kalahari village.

Authors:  S Kent; D Dunn
Journal:  Am J Trop Med Hyg       Date:  1993-04       Impact factor: 2.345

9.  Early alterations of red blood cell rheology in critically ill patients.

Authors:  Giulia Reggiori; Giovanna Occhipinti; Andrea De Gasperi; Jean-Louis Vincent; Michael Piagnerelli
Journal:  Crit Care Med       Date:  2009-12       Impact factor: 7.598

10.  Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?

Authors:  Demet Demirkol; Dincer Yildizdas; Benan Bayrakci; Bulent Karapinar; Tanil Kendirli; Tolga F Koroglu; Oguz Dursun; Nilgün Erkek; Hakan Gedik; Agop Citak; Selman Kesici; Metin Karabocuoglu; Joseph A Carcillo
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

View more
  105 in total

1.  Why and How Is Hyperferritinemic Sepsis Different From Sepsis Without Hyperferritinemia?

Authors:  Joseph A Carcillo; Kate K Kernan; Christopher M Horvat; Dennis W Simon; Rajesh K Aneja
Journal:  Pediatr Crit Care Med       Date:  2020-05       Impact factor: 3.624

Review 2.  Cutaneous Manifestations in Patients With COVID-19: Clinical Characteristics and Possible Pathophysiologic Mechanisms.

Authors:  F González González; C Cortés Correa; E Peñaranda Contreras
Journal:  Actas Dermosifiliogr       Date:  2021-01-28

3.  Circulating cell-free DNA, peripheral lymphocyte subsets alterations and neutrophil lymphocyte ratio in assessment of COVID-19 severity.

Authors:  Reham Hammad; Mona Abd El Rahman Eldosoky; Shaimaa Hani Fouad; Abdelaleem Elgendy; Amany M Tawfeik; Mohamed Alboraie; Mariam Fathy Abdelmaksoud
Journal:  Innate Immun       Date:  2021-03-01       Impact factor: 2.680

4.  Introduction: Autoinflammatory Syndromes Special Issue-hidden mysteries in the corners of autoinflammation.

Authors:  Scott W Canna; Raphaela Goldbach-Mansky
Journal:  Int Immunol       Date:  2018-04-25       Impact factor: 4.823

5.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

6.  Severe Yellow Fever and Extreme Hyperferritinemia Managed with Therapeutic Plasma Exchange.

Authors:  Jaques Sztajnbok; Ceila Maria Sant'Ana Malaque; Camila Hitomi Nihei; Irene Faria Duayer; Zita Maria Leme Britto; Eduarda Gambini Beraldo; Ralcyon Francis AzevedoTeixeira
Journal:  Am J Trop Med Hyg       Date:  2019-09       Impact factor: 2.345

7.  Understanding Disseminated Intravascular Coagulation and Hepatobiliary Dysfunction Multiple Organ Failure in Hyperferritinemic Critical Illness.

Authors:  Joseph A Carcillo; Bita Shakoory; Dennis Simon; Kate Kernan
Journal:  Pediatr Crit Care Med       Date:  2018-10       Impact factor: 3.624

Review 8.  Iron Homeostasis and Ferritin in Sepsis-Associated Kidney Injury.

Authors:  Kayla McCullough; Subhashini Bolisetty
Journal:  Nephron       Date:  2020-07-21       Impact factor: 2.847

9.  Anemia measurements to distinguish between viral and bacterial infections in the emergency department.

Authors:  Yael Steuerman; Asaf Wasserman; David Zeltser; Itzhak Shapira; Daniel Trotzky; Pinchas Halpern; Ahuva Meilik; Eli Raykhshtat; Shlomo Berliner; Ori Rogowski; Irit Gat-Viks; Shani Shenhar-Tsarfaty
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-06       Impact factor: 3.267

10.  The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome - a systematic review.

Authors:  J M Krei; H J Møller; J B Larsen
Journal:  Clin Exp Immunol       Date:  2020-11-23       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.